Skip to Content

PIK3CA Mutation Analysis

PIK3CA Mutation Analysis

Indication:  

Mutations in the PIK3CA gene have been identified in carcinomas arising from colon, breast, ovary, liver, stomach, and lung as well as in glioblastomas.  Evidence suggests that such mutations lead to constitutive activation of the PI3K pathway.  Mutations in PIK3CA are clustered and occur mainly in the helical (exon 9) and kinase (exon 20) domains of the protein.

Methodology:  

This test is performed by PCR-based Sanger sequencing of DNA to examine the mutation status of exons 9 and 20 of PIK3CA.

Test Parameters:  

This assay can detect mutations present in exons 9 and 20 of PIK3CA. The sensitivity of the Sanger sequencing assay is 20% of variant sequence in the background of wild-type sequence.

Turnaround Time:

7-10 days

Sample Requirements:
• 10 ug of purified DNA, sent on dry ice

or

• Four to six unstained recut slides of formalin-fixed, paraffin embedded tissue containing adequate amounts of tumor to be analyzed (See Sensitivity.)
The area of tumor to be analyzed should be indicated by circling the area on the bottom side of the slide or in a separate H&E-stained guide section.
Please provide a copy of the corresponding pathology report.

CPT Codes:

81479

Additional charges may apply for tissue extraction.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center